Loading…

Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film

Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in...

Full description

Saved in:
Bibliographic Details
Published in:BMC ophthalmology 2021-09, Vol.21 (1), p.1-319, Article 319
Main Authors: Sedlak, Lech, Świerczyńska, Marta, Borymska, Weronika, Zych, Maria, Wyględowska-Promieńska, Dorota
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343
cites cdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343
container_end_page 319
container_issue 1
container_start_page 1
container_title BMC ophthalmology
container_volume 21
creator Sedlak, Lech
Świerczyńska, Marta
Borymska, Weronika
Zych, Maria
Wyględowska-Promieńska, Dorota
description Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma
doi_str_mv 10.1186/s12886-021-02079-y
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2e8f1c01b5144616863c1673200b117b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A675229311</galeid><doaj_id>oai_doaj_org_article_2e8f1c01b5144616863c1673200b117b</doaj_id><sourcerecordid>A675229311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</originalsourceid><addsrcrecordid>eNp1kktv1DAQxyMEoqXwBThF4sKBFI_j2N4LUlXxWKkSFzhbfky23ib2YmdXbL8L3xWnW5UuAlmWLc9v_vPwVNVrIOcAkr_PQKXkDaFQNhGLZv-kOgUmoKEMuqeP7ifVi5zXpFCslc-rk5YxQTghp9Wv5bjRdqpjX7uYbuOgR-_wXW0w3OrhJga_HZtNwoxph-4xU-vg_oeZ5MMDF0OdcUA7zQYfR51uMOU5YvzpnZ78Dus8Fd9c-1BP11hPqFPd-2F8WT3r9ZDx1f15Vn3_9PHb5Zfm6uvn5eXFVWM7RqbGCWE6MMDROGmZkVb0hPJu4bS2VHCtJaXoDErHCNUdlw5NC2ApLLRpWXtWLQ-6Luq12iRfktyrqL26e4hppXSavB1QUZQ9WAIlIGMcuOStBS5aSogBEKZofThobbZmRGcxTEkPR6LHluCv1SrulGQAXUeKwNt7gRR_bDFPavTZ4jDogHGbFS35dwvOYUbf_IWu4zaF0qpCCcY7yjj_Q610KcCHPpa4dhZVF1x0lC5KLwp1_g-qLIejtzFg-RA8dqAHB5tizgn7hxqBqHlA1WFAVRlQdTegat_-Bob12kA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574652466</pqid></control><display><type>article</type><title>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</title><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><creator>Sedlak, Lech ; Świerczyńska, Marta ; Borymska, Weronika ; Zych, Maria ; Wyględowska-Promieńska, Dorota</creator><creatorcontrib>Sedlak, Lech ; Świerczyńska, Marta ; Borymska, Weronika ; Zych, Maria ; Wyględowska-Promieńska, Dorota</creatorcontrib><description>Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma</description><identifier>ISSN: 1471-2415</identifier><identifier>EISSN: 1471-2415</identifier><identifier>DOI: 10.1186/s12886-021-02079-y</identifier><identifier>PMID: 34470600</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Acids ; Age ; Analysis ; Antioxidants ; Benzalkonium chloride ; Biological markers ; Biomarkers ; Brinzolamide ; Carbonic anhydrase inhibitor ; Carbonic anhydrases ; Catalase ; Cornea ; Disease ; Dorzolamide ; Glaucoma ; Glutathione peroxidase ; Ocular surface ; Ophthalmology ; Oxidants ; Oxidative stress ; Pharmaceutical industry ; Preservatives ; Reagents ; Sulfhydryl groups ; Superoxide ; Superoxide dismutase ; Surface active agents</subject><ispartof>BMC ophthalmology, 2021-09, Vol.21 (1), p.1-319, Article 319</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</citedby><cites>FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411550/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2574652466?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids></links><search><creatorcontrib>Sedlak, Lech</creatorcontrib><creatorcontrib>Świerczyńska, Marta</creatorcontrib><creatorcontrib>Borymska, Weronika</creatorcontrib><creatorcontrib>Zych, Maria</creatorcontrib><creatorcontrib>Wyględowska-Promieńska, Dorota</creatorcontrib><title>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</title><title>BMC ophthalmology</title><description>Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma</description><subject>Acids</subject><subject>Age</subject><subject>Analysis</subject><subject>Antioxidants</subject><subject>Benzalkonium chloride</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Brinzolamide</subject><subject>Carbonic anhydrase inhibitor</subject><subject>Carbonic anhydrases</subject><subject>Catalase</subject><subject>Cornea</subject><subject>Disease</subject><subject>Dorzolamide</subject><subject>Glaucoma</subject><subject>Glutathione peroxidase</subject><subject>Ocular surface</subject><subject>Ophthalmology</subject><subject>Oxidants</subject><subject>Oxidative stress</subject><subject>Pharmaceutical industry</subject><subject>Preservatives</subject><subject>Reagents</subject><subject>Sulfhydryl groups</subject><subject>Superoxide</subject><subject>Superoxide dismutase</subject><subject>Surface active agents</subject><issn>1471-2415</issn><issn>1471-2415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kktv1DAQxyMEoqXwBThF4sKBFI_j2N4LUlXxWKkSFzhbfky23ib2YmdXbL8L3xWnW5UuAlmWLc9v_vPwVNVrIOcAkr_PQKXkDaFQNhGLZv-kOgUmoKEMuqeP7ifVi5zXpFCslc-rk5YxQTghp9Wv5bjRdqpjX7uYbuOgR-_wXW0w3OrhJga_HZtNwoxph-4xU-vg_oeZ5MMDF0OdcUA7zQYfR51uMOU5YvzpnZ78Dus8Fd9c-1BP11hPqFPd-2F8WT3r9ZDx1f15Vn3_9PHb5Zfm6uvn5eXFVWM7RqbGCWE6MMDROGmZkVb0hPJu4bS2VHCtJaXoDErHCNUdlw5NC2ApLLRpWXtWLQ-6Luq12iRfktyrqL26e4hppXSavB1QUZQ9WAIlIGMcuOStBS5aSogBEKZofThobbZmRGcxTEkPR6LHluCv1SrulGQAXUeKwNt7gRR_bDFPavTZ4jDogHGbFS35dwvOYUbf_IWu4zaF0qpCCcY7yjj_Q610KcCHPpa4dhZVF1x0lC5KLwp1_g-qLIejtzFg-RA8dqAHB5tizgn7hxqBqHlA1WFAVRlQdTegat_-Bob12kA</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Sedlak, Lech</creator><creator>Świerczyńska, Marta</creator><creator>Borymska, Weronika</creator><creator>Zych, Maria</creator><creator>Wyględowska-Promieńska, Dorota</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210901</creationdate><title>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</title><author>Sedlak, Lech ; Świerczyńska, Marta ; Borymska, Weronika ; Zych, Maria ; Wyględowska-Promieńska, Dorota</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acids</topic><topic>Age</topic><topic>Analysis</topic><topic>Antioxidants</topic><topic>Benzalkonium chloride</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Brinzolamide</topic><topic>Carbonic anhydrase inhibitor</topic><topic>Carbonic anhydrases</topic><topic>Catalase</topic><topic>Cornea</topic><topic>Disease</topic><topic>Dorzolamide</topic><topic>Glaucoma</topic><topic>Glutathione peroxidase</topic><topic>Ocular surface</topic><topic>Ophthalmology</topic><topic>Oxidants</topic><topic>Oxidative stress</topic><topic>Pharmaceutical industry</topic><topic>Preservatives</topic><topic>Reagents</topic><topic>Sulfhydryl groups</topic><topic>Superoxide</topic><topic>Superoxide dismutase</topic><topic>Surface active agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sedlak, Lech</creatorcontrib><creatorcontrib>Świerczyńska, Marta</creatorcontrib><creatorcontrib>Borymska, Weronika</creatorcontrib><creatorcontrib>Zych, Maria</creatorcontrib><creatorcontrib>Wyględowska-Promieńska, Dorota</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sedlak, Lech</au><au>Świerczyńska, Marta</au><au>Borymska, Weronika</au><au>Zych, Maria</au><au>Wyględowska-Promieńska, Dorota</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</atitle><jtitle>BMC ophthalmology</jtitle><date>2021-09-01</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>1</spage><epage>319</epage><pages>1-319</pages><artnum>319</artnum><issn>1471-2415</issn><eissn>1471-2415</eissn><abstract>Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><pmid>34470600</pmid><doi>10.1186/s12886-021-02079-y</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2415
ispartof BMC ophthalmology, 2021-09, Vol.21 (1), p.1-319, Article 319
issn 1471-2415
1471-2415
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2e8f1c01b5144616863c1673200b117b
source ProQuest - Publicly Available Content Database; PubMed Central
subjects Acids
Age
Analysis
Antioxidants
Benzalkonium chloride
Biological markers
Biomarkers
Brinzolamide
Carbonic anhydrase inhibitor
Carbonic anhydrases
Catalase
Cornea
Disease
Dorzolamide
Glaucoma
Glutathione peroxidase
Ocular surface
Ophthalmology
Oxidants
Oxidative stress
Pharmaceutical industry
Preservatives
Reagents
Sulfhydryl groups
Superoxide
Superoxide dismutase
Surface active agents
title Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T07%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20dorzolamide,%20benzalkonium-preserved%20dorzolamide%20and%20benzalkonium-preserved%20brinzolamide%20on%20selected%20biomarkers%20of%20oxidative%20stress%20in%20the%20tear%20film&rft.jtitle=BMC%20ophthalmology&rft.au=Sedlak,%20Lech&rft.date=2021-09-01&rft.volume=21&rft.issue=1&rft.spage=1&rft.epage=319&rft.pages=1-319&rft.artnum=319&rft.issn=1471-2415&rft.eissn=1471-2415&rft_id=info:doi/10.1186/s12886-021-02079-y&rft_dat=%3Cgale_doaj_%3EA675229311%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2574652466&rft_id=info:pmid/34470600&rft_galeid=A675229311&rfr_iscdi=true